InSphero Organ-on-a-Chip Solutions Featured in SLAS Technology

Akura™ Flow Organ on a Chip

The Akura™ Flow Organ on a Chip interconnects InSphero 3D human tissue models in organ networks

InSphero Logo

InSphero Logo

Early proof-of-concept studies demonstrate versatility of scalable microfluidic platform for 3D microtissue-based, multi-organ models

Our technology provides researchers with a completely new tool for studying complex diseases and discovering new cures.””

— Olivier Frey, PhD, InSphero Head of Technology and Platforms

SCHLIEREN, ZURICH, SWITZERLAND, February 1, 2019 /EINPresswire.com/ — The February 2019 issue of the scientific journal SLAS Technology showcases the innovative, scalable microfluidic platform that inspired InSphero’s new organ-on-a-chip system: Akura™ Flow. InSphero Head of Technology and Platforms Dr. Olivier Frey and co-authors from Prof. Andreas Hierlemann’s bioengineering lab at ETH Zürich were invited to contribute the article for the journal as top finalists for the prestigious SLAS Innovation Award in 2018.

InSphero has been testing and perfecting organ-on-a-chip solutions since 2011, when the company teamed up with ETH, AstraZeneca and other leading academic groups in the EU-supported research project Body-on-a-Chip, that aimed to mimic the response of the human body as a whole to drugs for safety and efficacy testing. Working in collaboration, microfluidics experts at ETH Zürich and InSphero, were able to refine early prototypes of the system and create the basis for a higher order system suitable for applications such as low clearance assays and metabolic disease modeling. InSphero has since been working on commercialization of the Akura™ Flow system to ensure the operational robustness and trustworthy results demanded by the pharmaceutical industry. Akura™ Flow is also the first technology to addresses important industry needs, such as short setup times of one week and the capability to automatically extract 3D microtissues from the device for downstream next-gen sequencing, histology or other rich endpoints.

Dr. Frey, who spearheads Akura™ Flow product development, says, “This is truly an exciting time to be working in the field of biomedical microfluidics. In partnership with our customers, we can now develop a wide range of multi-tissue configurations, from tumor-liver-immune system interactions for cancer research to liver-pancreatic islet communications for the study of metabolic diseases, such as diabetes and NASH. Our technology provides researchers with a completely new tool for studying complex diseases and discovering new cures.”

InSphero will be presenting on Akura™ Flow and 3D human tissue models for drug discovery and development at SLAS2019, Feb 2-6, in Washington, DC. The company will also be participating in the SLAS Exhibition and can be found at booth 848.

To read the SLAS Technology paper, “Scalable Microfluidic Platform for Flexible Configuration of and Experiments with Microtissue Multiorgan Models“, see: https://journals.sagepub.com/doi/abs/10.1177/2472630318802582?journalCode=jlad

To learn more about the Akura Flow organ-on-a-chip system, visit: https://insphero.com/science/enabling-technology/microphysiological-systems/

For more information about InSphero, visit www.insphero.com.

# # #

Frank Junker, Chief Business Officer
InSphero AG
+41 44 515 04 90
email us here
Visit us on social media:
Facebook
Twitter
LinkedIn


Source: EIN Presswire